Full Text
EE473 Cost-Efficiency Modeling of Conversion to Biosimilar Rituximab-pvvr in Diffuse Large B-Cell Lymphoma in Medicare

Abstract

Authors

Joshua A. Roth David Kratochvil Stephanie Dorman Wenjie Zhang

Back to Volume 28, Supplemental Issue 6S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×